Ionis Pharmaceuticals SEC Filings

Ionis Pharmaceuticals director reports option exercises and share sales. On 11/19/2025, the reporting person exercised non-qualified stock options to acquire 12,000 Ionis common shares at $40.05 and 32,000 shares at $63.90. The same day, they sold 12,000 shares and another 32,000 shares at a weighted average price of $72.1325 per share, in multiple trades within a stated price range. After these transactions, the insider beneficially owned 46,086 Ionis shares directly, and both option grants referenced in the filing were fully exercised, leaving no remaining derivative securities from those specific awards.

Ionis Pharmaceuticals, Inc. completed a private offering of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030. The zero-coupon notes are unsecured, mature on December 1, 2030, and can be converted into cash, Ionis common stock, or a combination, at the company’s election. The initial conversion rate is 10.1932 shares per $1,000 principal (about $98.10 per share), a roughly 35.0% premium to the November 12, 2025 stock price, with potential rate increases after certain corporate events.

Ionis estimates net proceeds of about $751.2 million. It used approximately $267.6 million to repurchase for cash $200.0 million principal amount of its 0% Convertible Senior Notes due 2026 and plans to use the remaining proceeds for additional repurchases of the 2026 notes and general corporate purposes. Based on the initial maximum conversion rate of 13.7608 shares per $1,000, up to 10,595,816 shares of common stock may initially be issuable upon conversion.

Ionis Pharmaceuticals (IONS) announced pivotal Phase 3 success for olezarsen in severe hypertriglyceridemia. The CORE and CORE2 studies met the primary endpoint, with olezarsen delivering a placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, sustained through 12 months. Olezarsen also achieved a highly statistically significant 85% reduction in adjudicated acute pancreatitis events, and 86% of treated patients reached triglyceride levels below 500 mg/dL.

Safety and tolerability were favorable: adverse events were balanced across arms, serious adverse events were less frequent than placebo, and injection-site reactions were the most common events. At 80 mg, asymptomatic liver enzyme elevations ≥3x ULN occurred in 7% vs 2% on placebo, with no Hy’s law cases and events generally resolving on treatment. Results were presented at the American Heart Association Scientific Sessions and published in NEJM. Ionis plans to submit a supplemental new drug application by year-end and expects a PDUFA target action date in 2026.

Ionis Pharmaceuticals (IONS) filed a Form 4 reporting an insider sale. EVP, Corp and Development Ops Brian Birchler sold 8,000 shares of common stock on 11/06/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024. The transaction was reported as a sale at a weighted average price of $76.1724, with individual trades executed between $76.00 and $76.32.

Following this transaction, Birchler beneficially owns 48,826 shares directly. The filing notes that detailed trade-by-trade pricing information within the range is available upon request.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales on November 5–6, 2025 under a Rule 10b5-1 trading plan adopted May 6, 2025.

He exercised non‑qualified stock options at $56.78 and $60.89 and sold the corresponding shares in multiple transactions at weighted average prices of $75.01, $76.0972, and $75.421 (with ranges disclosed in footnotes). Individual trades included 800 and 801 shares on November 5, and 14,738 and 18,300 shares on November 6. Following these transactions, Geary beneficially owns 59,657 shares directly.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary filed an amended Form 4 to correct share amounts. On 11/03/2025, he exercised stock options for 775 shares at $60.89 and 905 shares at $56.78, then sold 775 and 905 common shares at a $75.054 weighted average price, with trades ranging from $75.00 to $75.25.

Following these transactions, Geary beneficially owned 59,657 common shares directly. The amendment states it corrects the amounts reported in Column 4.

Ionis Pharmaceuticals (IONS): Director stock transactions disclosed. Director Joseph H. Wender reported open-market sales executed under a Rule 10b5-1 trading plan adopted on December 26, 2024. On 10/30/2025, the trust sold 2,484 shares at a weighted average price of $72.19, 8,341 shares at $73.16, and 5,975 shares at $73.85. On 10/31/2025, it sold 11,200 shares at a weighted average price of $75.1586.

Following these transactions, 64,035 shares were beneficially owned indirectly by a trust. The filing notes the reported prices are weighted averages from multiple trades within disclosed ranges, and detailed trade breakdowns are available upon request.

Ionis Pharmaceuticals (IONS): Director transaction reported. On 10/31/2025, director Joseph Loscalzo exercised a non-qualified stock option for 16,000 shares at an exercise price of $52.22 per share and sold 16,000 shares the same day. The reported sale price was a weighted average of $75.1043, with individual trades executed between $75.00 and $75.47.

The option originated from a grant exercisable since 07/03/2018 and expiring on 07/02/2027, and the director reported 0 derivative securities remaining afterward. Following these transactions, direct beneficial ownership was 36,330 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2024.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary, EVP and Chief Development Officer, reported option exercises and related sales. On 10/31/2025 and 11/03/2025, he exercised non-qualified stock options at $60.89 and $56.78, then sold shares pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025. Weighted average sale prices were $75.1083 (range $75.00–$75.47) and $75.054 (range $75.00–$75.25). Following these transactions, he beneficially owns 59,657 shares directly.